search
Back to results

Comparison of Closed-loop Operation After Morning Meal With and Without Carbohydrate Counting (CLASS02)

Primary Purpose

Type-1 Diabetes

Status
Completed
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
Dual Hormone closed-loop system
Sponsored by
Institut de Recherches Cliniques de Montreal
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type-1 Diabetes

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Males and females ≥ 18 and ≤ 65 years of old.
  • Clinical diagnosis of type 1 diabetes for at least one year. The diagnosis of type 1 diabetes is based on the investigator's judgment and medical history (e.g. history of acido-ketosis, etc.); C peptide level and antibody determinations are not needed.
  • The subject will have been on insulin pump therapy for at least 3 months.
  • Last (less than 3 months) HbA1c ≤ 12%.

Exclusion Criteria:

  • Clinically significant nephropathy, neuropathy (especially clinically significant gastroparesis) or retinopathy as judged by the investigator.
  • Recent (< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery.
  • Pregnancy.
  • Severe hypoglycemic episode within two weeks of screening.

    • Medication likely to affect with the interpretation of the results: Prandase, Victoza, Byetta and Symlin

  • Known or suspected allergy to the trial products or meal contents.
  • Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator.
  • Failure to comply with team's recommendations (e.g. not willing to eat snack, not willing to change pump parameters, etc).
  • Unreliable carbohydrate counting
  • Problems with venous access

Sites / Locations

  • Institut de Recherches Cliniques de Montréal (IRCM)

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

CHO-independent partial insulin bolus with closed-loop

CHO-dependent full insulin bolus combined with closed-loop

Arm Description

Outcomes

Primary Outcome Measures

Incremental area under the curve of plasma glucose concentration as compared to pre-meal glucose value of the postprandial glucose excursions

Secondary Outcome Measures

Percentage of postprandial time of plasma glucose concentrations spent in the high range (above 10.0 mmol/l).
Mean plasma glucose concentration.
Total insulin delivery
Total glucagon delivery
Plasma glucose concentration and incremental plasma glucose concentration at 2 hours postmeal
Postprandial peak and incremental postprandial peak of plasma glucose concentration
Percentage of time of plasma glucose concentrations spent in target range. Target range is defined to be between 4.0 and 10.0 mmol/l for 150 minutes postmeal and between 4.0 and 8.0 mmol/l afterwards
Percentage of postprandial time of plasma glucose concentrations spent in the low range (below 4.0mmol/l)

Full Information

First Posted
January 24, 2012
Last Updated
December 7, 2012
Sponsor
Institut de Recherches Cliniques de Montreal
Collaborators
McGill University, Montreal Children's Hospital of the MUHC
search

1. Study Identification

Unique Protocol Identification Number
NCT01519102
Brief Title
Comparison of Closed-loop Operation After Morning Meal With and Without Carbohydrate Counting
Acronym
CLASS02
Official Title
An Open-label, Randomized Two-way, Cross-over Study to Compare Meal-and-carbohydrate-announcement Strategy Versus Meal-announcement Strategy During Closed-loop Regulation of Glucose Levels in a Morning Meal in Adults With Type-1 Diabetes.
Study Type
Interventional

2. Study Status

Record Verification Date
December 2012
Overall Recruitment Status
Completed
Study Start Date
January 2012 (undefined)
Primary Completion Date
November 2012 (Actual)
Study Completion Date
November 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Institut de Recherches Cliniques de Montreal
Collaborators
McGill University, Montreal Children's Hospital of the MUHC

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosage based on the sensor's readings. A dual-hormone closed-loop system would regulate glucose levels through the infusion of two hormones: insulin and glucagon. The main goal of this project is to assess whether a dual-hormone closed-loop strategy would alleviate the burden of carbohydrate counting from patients with type 1 diabetes (T1D) without a significant degradation in post-meal glucose control. Each patient will be admitted twice to a clinical research facility. In one visit, patients will eat a morning meal accompanied with a matching insulin bolus (depending on the carbohydrate content of the meal) and glucose levels will be subsequently regulated using dual-hormone closed-loop system. In the other visit, patients will eat the same meal but will inject only a partial insulin bolus (not depending on carbohydrate content of the meal) and the remaining needed insulin will be delivered based on glucose sensor excursions as part of closed-loop operation. If post-meal glucose levels were indifferent between the two visits, then this would suggest that carbohydrate counting may not be necessary during closed-loop operation as the closed-loop system will give any remaining insulin needed to cover the glucose absorbed from the meal. Twelve subjects will be enrolled in this study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type-1 Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
12 (false)

8. Arms, Groups, and Interventions

Arm Title
CHO-independent partial insulin bolus with closed-loop
Arm Type
Active Comparator
Arm Title
CHO-dependent full insulin bolus combined with closed-loop
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
Dual Hormone closed-loop system
Intervention Description
The closed-loop system is composed of three components: continuous glucose system, insulin infusion pumps that infuses insulin and glucagon and a control algorithm that decides on the infusion rates based on sensor readings.
Primary Outcome Measure Information:
Title
Incremental area under the curve of plasma glucose concentration as compared to pre-meal glucose value of the postprandial glucose excursions
Time Frame
0-300min
Secondary Outcome Measure Information:
Title
Percentage of postprandial time of plasma glucose concentrations spent in the high range (above 10.0 mmol/l).
Time Frame
0-300 min
Title
Mean plasma glucose concentration.
Title
Total insulin delivery
Title
Total glucagon delivery
Title
Plasma glucose concentration and incremental plasma glucose concentration at 2 hours postmeal
Title
Postprandial peak and incremental postprandial peak of plasma glucose concentration
Title
Percentage of time of plasma glucose concentrations spent in target range. Target range is defined to be between 4.0 and 10.0 mmol/l for 150 minutes postmeal and between 4.0 and 8.0 mmol/l afterwards
Title
Percentage of postprandial time of plasma glucose concentrations spent in the low range (below 4.0mmol/l)
Time Frame
0-300min

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males and females ≥ 18 and ≤ 65 years of old. Clinical diagnosis of type 1 diabetes for at least one year. The diagnosis of type 1 diabetes is based on the investigator's judgment and medical history (e.g. history of acido-ketosis, etc.); C peptide level and antibody determinations are not needed. The subject will have been on insulin pump therapy for at least 3 months. Last (less than 3 months) HbA1c ≤ 12%. Exclusion Criteria: Clinically significant nephropathy, neuropathy (especially clinically significant gastroparesis) or retinopathy as judged by the investigator. Recent (< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery. Pregnancy. Severe hypoglycemic episode within two weeks of screening. • Medication likely to affect with the interpretation of the results: Prandase, Victoza, Byetta and Symlin Known or suspected allergy to the trial products or meal contents. Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator. Failure to comply with team's recommendations (e.g. not willing to eat snack, not willing to change pump parameters, etc). Unreliable carbohydrate counting Problems with venous access
Facility Information:
Facility Name
Institut de Recherches Cliniques de Montréal (IRCM)
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H2W 1R7
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
24656963
Citation
Haidar A, Farid D, St-Yves A, Messier V, Chen V, Xing D, Brazeau AS, Duval C, Boulet B, Legault L, Rabasa-Lhoret R. Post-breakfast closed-loop glucose control is improved when accompanied with carbohydrate-matching bolus compared to weight-dependent bolus. Diabetes Metab. 2014 Jun;40(3):211-4. doi: 10.1016/j.diabet.2013.12.001. Epub 2014 Mar 19.
Results Reference
derived

Learn more about this trial

Comparison of Closed-loop Operation After Morning Meal With and Without Carbohydrate Counting

We'll reach out to this number within 24 hrs